CRDO vs. KNSA
CRDO (Credo Technology Group Holding Ltd) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. CRDO operates in Semiconductors (Technology), while KNSA operates in Biotechnology (Healthcare). Over the past 3 years, CRDO returned 147.04%/yr vs 52.43%/yr for KNSA. At a 0.16 correlation, their price movements are largely independent.
Performance
CRDO vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRDO achieves a 88.92% return, which is significantly higher than KNSA's 33.60% return.
CRDO
- 1D
- 9.02%
- 1M
- 24.46%
- YTD
- 88.92%
- 6M
- 81.06%
- 1Y
- 217.89%
- 3Y*
- 147.04%
- 5Y*
- —
- 10Y*
- —
KNSA
- 1D
- 1.66%
- 1M
- 3.51%
- YTD
- 33.60%
- 6M
- 27.60%
- 1Y
- 93.78%
- 3Y*
- 52.43%
- 5Y*
- 29.69%
- 10Y*
- —
CRDO vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
CRDO Credo Technology Group Holding Ltd | 88.92% | 114.09% | 245.20% | 46.28% | 10.00% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 33.60% | 108.54% | 12.77% | 17.09% | 34.23% |
Correlation
The correlation between CRDO and KNSA is 0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.00 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.14 |
Correlation (All Time) Calculated using the full available price history since Jan 27, 2022 | 0.16 |
The correlation between CRDO and KNSA shifts across timeframes, from 0.00 (1 year) to 0.16 (all time), reflecting how their relationship changes across market environments.
Fundamentals
CRDO:
$52.38B
KNSA:
$4.54B
CRDO:
$2.50
KNSA:
$0.92
CRDO:
108.92
KNSA:
59.85
CRDO:
0.09
KNSA:
0.58
CRDO:
38.53
KNSA:
5.80
CRDO:
25.38
KNSA:
7.50
CRDO:
$1.34B
KNSA:
$754.05M
CRDO:
$908.35M
KNSA:
$294.06M
CRDO:
$463.79M
KNSA:
$101.06M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRDO vs. KNSA — Risk / Return Rank
CRDO
KNSA
CRDO vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Credo Technology Group Holding Ltd (CRDO) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRDO | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.27 | ||
| Sortino ratioReturn per unit of downside risk | -0.50 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.41 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 4.09 | 4.63 | -0.55 |
| Martin ratioReturn relative to average drawdown | 9.86 | 16.35 | -6.50 |
Loading charts...
Drawdowns
CRDO vs. KNSA - Drawdown Comparison
The maximum CRDO drawdown since its inception was -62.04%, smaller than the maximum KNSA drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for CRDO and KNSA.
Loading charts...
Drawdown Indicators
| CRDO | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.04% | -83.06% | +21.02% |
Max Drawdown (1Y)Largest decline over 1 year | -53.59% | -21.12% | -32.47% |
Max Drawdown (3Y)Largest decline over 3 years | -61.05% | -34.14% | -26.91% |
Max Drawdown (5Y)Largest decline over 5 years | — | -53.17% | — |
Current DrawdownCurrent decline from peak | 0.00% | -7.35% | +7.35% |
Average DrawdownAverage peak-to-trough decline | -19.33% | -40.60% | +21.27% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.18% | 5.97% | +16.21% |
Volatility
CRDO vs. KNSA - Volatility Comparison
Credo Technology Group Holding Ltd (CRDO) has a higher volatility of 26.28% compared to Kiniksa Pharmaceuticals, Ltd. (KNSA) at 10.40%. This indicates that CRDO's price experiences larger fluctuations and is considered to be riskier than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRDO | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 26.28% | 10.40% | +15.88% |
Volatility (6M)Calculated over the trailing 6-month period | 65.88% | 34.02% | +31.86% |
Volatility (1Y)Calculated over the trailing 1-year period | 86.27% | 43.03% | +43.24% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 81.58% | 53.48% | +28.10% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 81.58% | 63.93% | +17.65% |
Dividends
CRDO vs. KNSA - Dividend Comparison
Neither CRDO nor KNSA has paid dividends to shareholders.
Financials
CRDO vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between Credo Technology Group Holding Ltd and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CRDO vs. KNSA - Profitability Comparison
CRDO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Credo Technology Group Holding Ltd reported a gross profit of 298.07M and revenue of 437.00M. Therefore, the gross margin over that period was 68.2%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.
CRDO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Credo Technology Group Holding Ltd reported an operating income of 155.85M and revenue of 437.00M, resulting in an operating margin of 35.7%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.
CRDO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Credo Technology Group Holding Ltd reported a net income of 169.10M and revenue of 437.00M, resulting in a net margin of 38.7%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.
Frequently Asked Questions
CRDO and KNSA have a correlation of 0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRDO has higher volatility (26.28%) compared to KNSA (10.40%). In terms of maximum drawdown, CRDO dropped -62.04% vs KNSA's -83.06%.
CRDO currently has the higher Sharpe Ratio (2.55 vs 2.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRDO and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer